Purpose Adjuvant cisplatin-based chemotherapy (ACT) is now an accepted standard for
completely resected stage II and III A non–small-cell lung cancer (NSCLC). Long-term follow-up …

… randomized studies is largely lacking. To address this gap, we undertook a prospective
randomized phase I/II trial in which the phase I … regimens, and the phase II component evaluated …

… Etoposide and cisplatin (EP) has been a standard treatment for extensive-disease small-cell
lung cancer (SCLC). An earlier phase III trial reported improved survival for patients …

Purpose To evaluate the efficacy and safety of dulanermin combined with paclitaxel and
carboplatin (PC) and bevacizumab (PCB) as first-line treatment for advanced or recurrent non–…

… , lung cancer continues to be the leading cause of cancer deaths in … cancer combined.
Radical surgery remains the cornerstone of treatment for early-stage non–small-cell lung cancer (…

Purpose We conducted a phase III study to compare the survival impact of concurrent versus
sequential treatment with radiotherapy (RT) and chemotherapy (CT) in unresectable stage …

… A Japanese randomized trial showed superior survival for patients with extensive-disease
(ED) small-cell lung cancer (SCLC) receiving irinotecan plus cisplatin compared with …

… The primary end point of this open-label, randomized phase II study was progression-free
survival (PFS). Patients with non-progressive, advanced NSCLC after platinum-based doublet (…

… lung cancers. At diagnosis, approximately 40% of the patients will present with limited-stage
disease (LD), while 60% will have extensive-stage … Although randomized phase III studies …

… phase II results of docetaxel monotherapy, this phase III trial was conducted of chemotherapy
for patients with advanced non–small-cell lung cancer … patients were randomized to receive …